---
schema_version: "secwatch.filing_event.v1"
accession: "0001650664-26-000082"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2026-08-05T20:03:09+00:00"
generated_at: "2026-08-05T20:04:34.859747+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Editas Medicine Q2 net loss narrows to $18.2M; EDIT-401 on track for CTN submission

## Summary
- Net loss $18.2M ($0.15/sh) vs $53.2M ($0.63/sh) in Q2 2025; collaboration revenue up to $11.9M.
- Cash $211.6M as of June 30, 2026, up from $146.6M; cash runway into H2 2028.
- EDIT-401 preclinical data shows ~90% mean reduction in LDL-C, Lp(a), ApoB in NHPs; CTN submission planned this month.
- Phase 1/2 trial for HeFH to start; data update expected Q1 2027.
- Board: Elliott Levy resigned; Patrick Ellinor appointed as independent director.

## SEC filing metadata
- accession: 0001650664-26-000082
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2026-08-05T20:03:09+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000165066426000082/0001650664-26-000082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000165066426000082/edit-20260803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001650664-26-000082
- JSON: https://secwatch.observer/filing/0001650664-26-000082.json
- Plain text: https://secwatch.observer/filing/0001650664-26-000082.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.